South Korea · Delayed Price · Currency is KRW BioSmart Statistics
Total Valuation
BioSmart has a market cap or net worth of KRW 66.98 billion. The enterprise value is 167.04 billion.
| Market Cap | 66.98B |
| Enterprise Value | 167.04B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioSmart has 25.27 million shares outstanding. The number of shares has increased by 9.67% in one year.
| Current Share Class | 25.27M |
| Shares Outstanding | 25.27M |
| Shares Change (YoY) | +9.67% |
| Shares Change (QoQ) | -1.66% |
| Owned by Insiders (%) | 25.58% |
| Owned by Institutions (%) | 4.46% |
| Float | 18.54M |
Valuation Ratios
The trailing PE ratio is 4.98.
| PE Ratio | 4.98 |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 3.35 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 12.38 |
| EV / Sales | 0.30 |
| EV / EBITDA | 4.99 |
| EV / EBIT | 6.24 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.44 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 2.70 |
| Debt / FCF | -4.24 |
| Interest Coverage | 9.57 |
Financial Efficiency
Return on equity (ROE) is 9.83% and return on invested capital (ROIC) is 8.70%.
| Return on Equity (ROE) | 9.83% |
| Return on Assets (ROA) | 5.57% |
| Return on Invested Capital (ROIC) | 8.70% |
| Return on Capital Employed (ROCE) | 12.82% |
| Weighted Average Cost of Capital (WACC) | 4.86% |
| Revenue Per Employee | 3.33B |
| Profits Per Employee | 79.81M |
| Employee Count | 169 |
| Asset Turnover | 1.78 |
| Inventory Turnover | 7.82 |
Taxes
In the past 12 months, BioSmart has paid 5.49 billion in taxes.
| Income Tax | 5.49B |
| Effective Tax Rate | 23.12% |
Stock Price Statistics
The stock price has decreased by -14.52% in the last 52 weeks. The beta is 0.74, so BioSmart's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -14.52% |
| 50-Day Moving Average | 2,699.30 |
| 200-Day Moving Average | 3,586.63 |
| Relative Strength Index (RSI) | 44.94 |
| Average Volume (20 Days) | 109,722 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSmart had revenue of KRW 562.68 billion and earned 13.49 billion in profits. Earnings per share was 532.38.
| Revenue | 562.68B |
| Gross Profit | 87.49B |
| Operating Income | 28.13B |
| Pretax Income | 23.75B |
| Net Income | 13.49B |
| EBITDA | 34.80B |
| EBIT | 28.13B |
| Earnings Per Share (EPS) | 532.38 |
Balance Sheet
The company has 41.31 billion in cash and 94.05 billion in debt, with a net cash position of -52.74 billion or -2,086.67 per share.
| Cash & Cash Equivalents | 41.31B |
| Total Debt | 94.05B |
| Net Cash | -52.74B |
| Net Cash Per Share | -2,086.67 |
| Equity (Book Value) | 197.41B |
| Book Value Per Share | 5,989.63 |
| Working Capital | 55.03B |
Cash Flow
In the last 12 months, operating cash flow was 19.99 billion and capital expenditures -42.18 billion, giving a free cash flow of -22.19 billion.
| Operating Cash Flow | 19.99B |
| Capital Expenditures | -42.18B |
| Depreciation & Amortization | 6.67B |
| Net Borrowing | 35.13B |
| Free Cash Flow | -22.19B |
| FCF Per Share | -877.93 |
Margins
Gross margin is 15.55%, with operating and profit margins of 5.00% and 2.40%.
| Gross Margin | 15.55% |
| Operating Margin | 5.00% |
| Pretax Margin | 4.22% |
| Profit Margin | 2.40% |
| EBITDA Margin | 6.18% |
| EBIT Margin | 5.00% |
| FCF Margin | n/a |
Dividends & Yields
BioSmart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.67% |
| Shareholder Yield | -9.67% |
| Earnings Yield | 20.14% |
| FCF Yield | -33.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2010. It was a reverse split with a ratio of 0.16667.
| Last Split Date | Sep 20, 2010 |
| Split Type | Reverse |
| Split Ratio | 0.16667 |
Scores
BioSmart has an Altman Z-Score of 2.71 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.71 |
| Piotroski F-Score | 6 |